Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

While Ozempic is effective at treating type 2 diabetes and supporting weight loss, it can also come with side effects.

The company has looked internally for its new leader, as Doustdar is currently serving as its head of international ...

Caliway receives US FDA clearance to proceed with SUPREME-01 phase 3 study of CBL-514 for reducing abdominal subcutaneous fat: New Taipei City Tuesday, July 29, 2025, 14:00 Hrs [I ...

Q: I wish I could go to a doctor who could outline a personalized plan for improving and protecting my health, but that’s ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.